Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfag084 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Sajal Tiwary und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St.Louis, MO, United States. Hauptthemen laut MEDLINE: Procalcitonin, Tissue Inhibitor of Metalloproteinase-1, Microfilament Proteins, Muscle Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Bloodstream infections (BSI) are a significant contributor to morbidity and mortality among hospitalized patients. Rapid diagnosis of BSI is critical for timely and appropriate clinical management, but current diagnostic strategies have a prolonged turnaround time or only identify select pathogens with minimal prognostic information.
Methods
We examined serial serologic samples from 77 intensive care unit (ICU) patients at time points before, during, and after diagnosis of presumptive BSI to identify host-derived protein biomarkers associated with specific organisms and with clinical outcomes in BSI. ICU patients with and without BSI were included. Two candidate biomarkers, tissue metalloproteinase 1 (TIMP-1) and transgelin-2 (transgelin), were analyzed using enzyme-linked immunosorbent assay (ELISA) analysis and with procalcitonin (PCT) as a positive control.
Results
TIMP-1 was higher in those with gram-negative BSI [median = 746 ng/mL, interquartile range (IQR): 355–1410] than gram-positive BSI (662 ng/mL, 396–1111), and culture negative (377 ng/mL, 189–708). For transgelin, those with gram-negative BSI were highest (14.6 ng/mL, 9.6–22.0), followed by gram-positive BSI (9 ng/mL, 6.1–16), and negative cultures (9.1 ng/mL, 5.6–13.0). PCT was highest among patients with gram-positive BSI (10.8 ng/mL, 1.3–23.3), followed by gram-negative BSI (7.7 ng/mL, 1.6–57.7), and negative cultures (1.2 ng/mL, 0.3–3.5). The multiplicative product of all 3 markers had an AUC of 0.8 (0.7–0.9). No biomarker was associated with risk for ICU admission, 30-day mortality, or length of stay.
Conclusion
TIMP1 and transgelin-2 are candidate biomarkers for diagnosing BSI. Larger studies comparing their utility to PCT and other sepsis biomarkers are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St.Louis, MO, United States.
- Department of Pathology & Immunology, Washington University School of Medicine, St.Louis, MO, United States.
ORCID-Profile: Christopher W Farnsworth
Zitieren
APA
Tiwary, S., O'Neil, C. A., Lawless, S., Arter, O., Brown, M., Roemmich, B., Samuels, C., Kwon, J. H., & Farnsworth, C. W. (2026). Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfag084
Vancouver
Tiwary S, O'Neil CA, Lawless S, Arter O, Brown M, Roemmich B, et al. Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfag084
BibTeX
@article{Tiwary2026,
author = {Tiwary, Sajal and O'Neil, Caroline A and Lawless, Sydney and Arter, Olivia and Brown, Meghan and Roemmich, Brittany and Samuels, Carleigh and Kwon, Jennie H and Farnsworth, Christopher W},
title = {Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfag084}
}
EUVIMED